March Biosciences’ MB-105 Receives the Regenerative Medicine Advanced Therapy Designation for R/R CD5+ T-Cell Lymphoma

Shots:The US FDA has granted RMAT designation to MB-105 for the treatment of r/r CD5-positive T-cell lymphomaDesignation was based on the ongoing P-II trial, which showed clinical activity with a favorable safety profile; initial data to be presented at ASH’25, with additional updates expected in 2026March Bio will pursue clinical & commercial…